MIST Latest Press Releases

-- November 3, 2026 --

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:45 PM

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026 Globe Newswire 8:00 AM

-- November 2, 2026 --

New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation Globe Newswire 8:00 AM

-- October 19, 2026 --

Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences Globe Newswire 8:00 AM

-- October 9, 2026 --

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial Globe Newswire 8:00 AM

-- September 24, 2026 --

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR Globe Newswire 8:00 AM

-- September 3, 2026 --

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States Globe Newswire 9:35 AM

-- September 2, 2026 --

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences Globe Newswire 8:00 AM

-- August 27, 2026 --

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes Globe Newswire 8:00 AM

-- August 21, 2026 --

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) Globe Newswire 8:00 AM

-- August 12, 2026 --

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:08 AM

-- August 4, 2026 --

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026 Globe Newswire 4:01 PM

-- July 2, 2026 --

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 9:30 PM

-- June 23, 2026 --

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board Business Wire 8:30 AM

Market Data Delayed 15 Minutes